Fulgent Genetics (FLGT) vs MDxHealth SA (MDXH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Fulgent Genetics (FLGT) has outperformed MDxHealth SA (MDXH) over the past year, losing 8.8% versus a loss of 87.2%. Fulgent Genetics is the larger company by market cap ($596.1 million vs $55.4 million), about 10.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FLGT | MDXH |
|---|---|---|
| Share price | $21.67 | $0.581 |
| Market cap | $596.12M | $55.44M |
| 1-day change | +4.06% | +0.09% |
| YTD return | -20.75% | -83.74% |
| 1-year return | -8.80% | -87.16% |
| 5-year return | -73.31% | — |
| EPS (TTM) | $-2.82 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.04 | $5.33 |
| 52-week low | $13.46 | $0.40 |
| Distance from 52-week high | -30.20% | -89.10% |
| Analyst consensus | none | none |
| Avg. price target upside | -12.30% | +209.81% |
| Average volume | 301.04K | 5.69M |
| Shares outstanding | 27.52M | 95.42M |
| Employees | 1,315 | 364 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Fulgent Genetics is about 10.8 times larger than MDxHealth SA by market value ($596.12M vs $55.44M).
- FLGT has outperformed MDXH by 78.4 percentage points over the past year.
About Fulgent Genetics
FLGT stock →Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
Health Care · Medical Specialities · 1,315 employees
About MDxHealth SA
MDXH stock →MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Health Care · Medical Specialities · 364 employees
FLGT vs MDXH FAQ
Which is bigger, Fulgent Genetics or MDxHealth SA?
Fulgent Genetics (FLGT) is larger, with a market capitalization of $596.12M compared with $55.44M for MDxHealth SA (MDXH).
Which stock has performed better over the past year, FLGT or MDXH?
FLGT returned -8.80% over the past 12 months, compared with -87.16% for MDXH (price return, excluding dividends). Past performance does not predict future results.
Are Fulgent Genetics and MDxHealth SA in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.